BR112022005465A2 - Conjugados de proteína-macromolécula e métodos de uso dos mesmos - Google Patents

Conjugados de proteína-macromolécula e métodos de uso dos mesmos

Info

Publication number
BR112022005465A2
BR112022005465A2 BR112022005465A BR112022005465A BR112022005465A2 BR 112022005465 A2 BR112022005465 A2 BR 112022005465A2 BR 112022005465 A BR112022005465 A BR 112022005465A BR 112022005465 A BR112022005465 A BR 112022005465A BR 112022005465 A2 BR112022005465 A2 BR 112022005465A2
Authority
BR
Brazil
Prior art keywords
protein
conjugates
methods
macromolecule
macromolecule conjugates
Prior art date
Application number
BR112022005465A
Other languages
English (en)
Inventor
Chuan Liao
Haiping Zhou
Hui Li
Yuntao Song
Original Assignee
Beijing Xuanyi Pharmasciences Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Xuanyi Pharmasciences Co Ltd filed Critical Beijing Xuanyi Pharmasciences Co Ltd
Publication of BR112022005465A2 publication Critical patent/BR112022005465A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

conjugados de proteína-macromolécula e métodos de uso dos mesmos. a presente invenção refere-se a conjugados de proteína-macromolécula, ligantes liberáveis e macromoléculas, conforme definido neste documento. os conjugados divulgados fornecem propriedades únicas que são baseadas, pelo menos, nas propriedades do ligante e no número de frações ligante-macromolécula. também são fornecidos neste documento um método de síntese e uso de conjugados no tratamento de doenças e distúrbios.
BR112022005465A 2019-09-30 2020-09-30 Conjugados de proteína-macromolécula e métodos de uso dos mesmos BR112022005465A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962908435P 2019-09-30 2019-09-30
PCT/US2020/053572 WO2021067458A1 (en) 2019-09-30 2020-09-30 Protein-macromolecule conjugates and methods of use thereof

Publications (1)

Publication Number Publication Date
BR112022005465A2 true BR112022005465A2 (pt) 2022-06-14

Family

ID=75337536

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022005465A BR112022005465A2 (pt) 2019-09-30 2020-09-30 Conjugados de proteína-macromolécula e métodos de uso dos mesmos

Country Status (12)

Country Link
US (1) US20220401561A1 (pt)
EP (1) EP4037715A4 (pt)
JP (1) JP2022549295A (pt)
KR (1) KR20220074897A (pt)
CN (1) CN114630818A (pt)
AU (1) AU2020360397A1 (pt)
BR (1) BR112022005465A2 (pt)
CA (1) CA3153644A1 (pt)
IL (1) IL291730A (pt)
MX (1) MX2022003065A (pt)
TW (1) TW202126332A (pt)
WO (1) WO2021067458A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022103983A2 (en) * 2020-11-11 2022-05-19 Sutro Biopharma, Inc. Fluorenylmethyloxycarbonyl and fluorenylmethylaminocarbonyl compounds, protein conjugates thereof, and methods for their use
CN113929731B (zh) * 2021-12-16 2022-05-10 北京春雷杰创生物科技有限公司 一种促进低分子量蛋白体外复性和提高免疫原性的方法
WO2023244517A1 (en) * 2022-06-16 2023-12-21 Merck Sharp & Dohme Llc Interleukin-2 prodrugs
CN115947745B (zh) * 2022-12-26 2024-02-27 中山大学 一种基于白蛋白的光热转换纳米材料及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100240773A1 (en) * 2009-03-23 2010-09-23 Kenneth Korzekwa Multifunctional linkers
WO2011140393A1 (en) * 2010-05-05 2011-11-10 Prolynx Llc Controlled release from macromolecular conjugates
WO2011140376A1 (en) * 2010-05-05 2011-11-10 Prolynx Llc Controlled drug release from dendrimers
WO2011140392A1 (en) * 2010-05-05 2011-11-10 Prolynx Llc Controlled drug release from solid supports
CA2848142C (en) * 2011-09-07 2021-05-18 Prolynx Llc Hydrogels with biodegradable crosslinking
WO2013036857A1 (en) * 2011-09-07 2013-03-14 Prolynx Llc Sulfone linkers
WO2013059323A1 (en) * 2011-10-18 2013-04-25 Prolynx Llc Peg conjugates of exenatide
SG10201803370XA (en) * 2013-10-22 2018-06-28 Prolynx Llc Conjugates of somatostatin and its analogs
WO2016053107A1 (en) * 2014-10-03 2016-04-07 Synaffix B.V. Sulfamide linker, conjugates thereof, and methods of preparation

Also Published As

Publication number Publication date
JP2022549295A (ja) 2022-11-24
KR20220074897A (ko) 2022-06-03
EP4037715A1 (en) 2022-08-10
CN114630818A (zh) 2022-06-14
MX2022003065A (es) 2022-06-09
AU2020360397A1 (en) 2022-03-31
US20220401561A1 (en) 2022-12-22
WO2021067458A1 (en) 2021-04-08
CA3153644A1 (en) 2021-04-08
EP4037715A4 (en) 2023-12-13
TW202126332A (zh) 2021-07-16
IL291730A (en) 2022-05-01

Similar Documents

Publication Publication Date Title
BR112022005465A2 (pt) Conjugados de proteína-macromolécula e métodos de uso dos mesmos
MX2019005911A (es) Anticuerpos anti_cd137 novedosos y usos de estos.
CY1123884T1 (el) Αντισωματα enanti-cd123 και συζευγματα και παραγωγα αυτων
CY1122472T1 (el) Συζευγμα-αντισωματος-φαρμακου και η χρηση αυτου για την αγωγη του καρκινου
MX2020002666A (es) Conjugados de anticuerpos anti-receptor de folato, composiciones que contienen conjugados de anticuerpos anti-receptor de folato y metodos de fabricación y uso de conjugados de anticuerpos anti-receptor de folato.
CY1119925T1 (el) Aνti-cd40 αντισωματα, χρησεις και μεθοδοι
CY1120670T1 (el) Μονοκλωνικα αντισωματα εναντι του αναστολεα μονοπατιου ιστικου παραγοντα (tfpi)
MX2017014908A (es) Proteinas de union triespecificas y metodos de uso.
CY1119219T1 (el) Anti-ceacam5 αντισωματα και χρησεις αυτων
BR112021023229A2 (pt) Conjugados anticorpo-fármaco inibidores de mcl-1 e métodos de uso
BR112018012164A2 (pt) anticorpos neutralizantes do vírus da imunodeficiência humana
BR112018071276A2 (pt) anticorpos anti-il-33, composições, métodos e usos dos mesmos
CU20170169A7 (es) Anticuerpos de factor xi
EA201690744A1 (ru) Конъюгаты белок-полимер-лекарственное средство
EA201991763A1 (ru) Конъюгаты антитела к ccr7 и лекарственного средства
BR112017013661A2 (pt) conjugado derivado de antraciclina (pnu), conjugado de fármaco-proteína de ligação (bpdc), método para a produção de um conjugado de fármaco-proteína de ligação (bpdc), uso de um conjugado de proteína de ligação-fármaco (bpdc) e composição farmacêutica
MX366503B (es) Derivados de amatoxina.
CY1121783T1 (el) Συζευγμα αντισωματος-igf-1r-φαρμακου και η χρηση αυτου για την αγωγη του καρκινου
BR112021005702A8 (pt) Método para selecionar neoepítopos
BR112022011074A2 (pt) Métodos para preparar n6-((2-azidoetóxi)carbonil)lisina
CY1121187T1 (el) Ενα εκχυλισμα απο indigo naturalis και μια διεργασια για την παρασκευη εκεινου
BR112022005026A2 (pt) Conjugados terapêuticos
BR112022002579A2 (pt) Anticorpos contra ilt2 e uso dos mesmos
EA201991196A1 (ru) Претерпевшие самосборку диблок-сополимеры, состоящие из pegmema и несущих лекарственное средство полимерных сегментов
BR112021011729A2 (pt) Tubulisinas e conjugados de proteína-tubulisina